On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.

The most recent market update indicated the pullback followed short-term profit-taking after the stock had been lifted by two earlier catalysts: Citi adding WUXI BIO to its 90-day upside catalyst watch list and expectations for a possible fourth-quarter full-year guidance increase, as well as the company’s exclusive development agreement with Fresenius.

Under that agreement, Fresenius received exclusive option rights over up to 37 identified biosimilar candidates over 10 years in what has been described as the largest biosimilar development deal announced so far. The fee-for-service structure is viewed by the market as supportive of medium- to long-term order visibility. The latest market note also showed broader weakness across related names, including WUXI APPTEC, WUXI XDC and PHARMARON, suggesting sector pressure compounded the decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)